GAM
KRYS icon

Gotham Asset Management’s Krystal Biotech KRYS Stock Holding History

Gotham Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Buy
1,330
+7
+0.5% +$2.09K ﹤0.01% 1517
2026
Q1 		$342K Buy
1,323
+20
+2% +$5.32K ﹤0.01% 1579
2025
Q4 		$321K Sell
1,303
-4
-0.3% -$842 ﹤0.01% 1552
2025
Q3 		$231K Buy
+1,307
New +$196K ﹤0.01% 1580
2025
Q2 		– Sell
-4,804
Closed -$866K – 1707
2025
Q1 		$866K Buy
+4,804
New +$808K 0.01% 1049

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gotham Asset Management's KRYS Position: Q2 2026 in Review

Gotham Asset Management increased its Krystal Biotech (KRYS) stake by 0.53% in Q2 2026, buying an estimated $2.09K and bringing the position to 1,330 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Gotham Asset Management first reported a position in KRYS in Q1 2025 and has held it in 5 quarters since. The position peaked at $866K in Q1 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Gotham Asset Management held 1,330 shares of Krystal Biotech worth $494K as of Q2 2026.
  • Gotham Asset Management bought 7 Krystal Biotech shares in Q2 2026, an estimated $2.09K.
  • Krystal Biotech made up ﹤0.01% of Gotham Asset Management's portfolio in Q2 2026, its #1517 holding.
  • Gotham Asset Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 5 quarters since.
  • Gotham Asset Management's Krystal Biotech position peaked at $866K in Q1 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.